News

The ongoing COVID-19 pandemic is disrupting vital care and support for those with neurological disorders like multiple sclerosis (MS), according to a recent report from the Neurological Alliance in the U.K. The report is based upon survey responses from over 1,600 people with neurological conditions in that…

More than half of people with brain imaging changes akin to multiple sclerosis (MS) go on to develop the disease within 10 years, a global study of those with radiologically isolated syndrome reported. Progression to MS appears to be more likely in those who are younger, have spinal…

Complementary and alternative medicines are increasingly popular among people with multiple sclerosis (MS) in the northwestern United States, a survey found. More than 80% of the 1,000 people who responded to the Oregon Health & Science University (OHSU) survey reported using supplements and exercise to help treat their MS, and…

Progentec has established new licensing agreements with Stanford University and the Oklahoma Medical Research Foundation to commercialize and sell laboratory technologies related to multiple sclerosis (MS), the company announced. The technologies include laboratory tests for the prediction of MS relapses, measurements of MS disease activity, classification of…

The Australian Government’s Medical Research Future Fund (MRFF) has awarded AU$7.1 million (about $4.95 million) to support two projects focused on harnessing the power of artificial intelligence (AI) and machine learning to develop new ways of diagnosing and treating multiple sclerosis (MS) and mental health disorders in young people.

The Multiple Sclerosis Society of Canada and its partner, the Canadian Institutes of Health Research (CIHR), have invested CA$1.5 million to open a clinical trial that will investigate the potential of two cannabis derivatives — cannabidiol (CBD) and tetrahydrocannabinol (THC) — in treating spasticity (muscle stiffness) and other…

JuneBrain, a startup company that is developing a wearable head imaging device that enables multiple sclerosis (MS) patients to remotely monitor their disease activity and treatment response, has received a $50,000 investment through TEDCO’s Builder Fund, the investor announced. MS is caused by inflammation in the…

Immune B-cells that proliferate unchecked when infected by the Epstein-Barr virus (EBV) appear to increase the risk of relapses in patients with multiple sclerosis (MS), a mouse study suggests. The study, “Epstein Barr virus‐immortalized B lymphocytes exacerbate experimental autoimmune encephalomyelitis in xenograft mice,” was published…

Disability appears to mostly accumulate in people with relapsing forms of multiple sclerosis (MS) in a progressive manner — rather than being due to relapses, a pooled analysis of patients in two Ocrevus (ocrelizumab) clinical trials shows. These findings, indicating that disease progression underlies relapsing MS as well,…

Dragonfly Therapeutics and Bristol Myers Squibb (BMS) announced an expanded partnership focused on discovering and developing treatment candidates for multiple sclerosis (MS) and neuroinflammation targets. The companies have been working together in therapy research and development for cancer and autoimmune diseases using Dragonfly’s proprietary immunotherapy targeting platform.

Switching to Ocrevus (ocrelizumab) within a relatively short period is a safe and effective option for people with relapsing-remitting multiple sclerosis (RRMS) who stop treatment with Tysabri (natalizumab), a small and retrospective analysis suggests. With a median washout period of six weeks between therapies, the 28 patients in this study…

Mavenclad (cladribine) prevents relapses and disease progression in more than half of patients with relapsing forms of multiple sclerosis (MS) for at least five years after the last dose, according to a real-life study from Italy. These findings, based on real-world data from Italian MS patients previously treated…

The German Federal Ministry of Education and Research (BMBF) has granted €1.2 million ($1.35 million) to support a project seeking to characterize the function of the protein TRPM4, a potential therapeutic target to prevent nerve cell injury associated with multiple sclerosis (MS), and to develop new drug candidates…

Young men, ages 16 to 20, with a higher the body mass index (BMI) are at greater their risk of being diagnosed with multiple sclerosis (MS) later in life, regardless of physical fitness, according to a Swedish study. Risk rose across “the entire BMI range,” its researchers reported,…

Tecfidera (dimethyl fumarate) is as safe and effective in Hispanic/Latino multiple sclerosis (MS) patients as it is in their non-Hispanic and non-Latino peers, three-year data from a real-world study show. These interim findings, based on the largest group of Tecfidera-treated Hispanic and Latino MS patients studied to date, support the therapy’s…

The University of Alberta and PROTXX are collaborating to develop wearable sensors for people with multiple sclerosis (MS) and advance a remote healthcare platform that facilitates personalized care and reduces frequency of hospital visits. The wearable sensors will help monitor neurological, sensory, and musculoskeletal symptoms without the need to…

Osmotica Pharmaceuticals has submitted an amended new drug application (NDA) to the U.S. Food and Drug Administration (FDA) requesting the approval of arbaclofen extended release (ER) tablets for the treatment of spasticity in people with multiple sclerosis (MS). Arbaclofen ER (brand name…

Comorbidities such as anxiety and depression are associated with a significantly increased risk of relapse in people with relapsing-remitting multiple sclerosis (RRMS), a clinical trial analysis has found.  Anxiety and abnormal blood lipids (fats) also increased the risk of any RRMS disease activity.  Based on those findings, researchers…

Exposure to disease-modifying therapies does not increase multiple sclerosis (MS) patients’ risk of developing a severe form of COVID-19, according to a registry-based study. However, MS patients who are older, obese, or have severe neurological impairments have a greater risk of developing a severe form of the disease. Findings…

GeNeuro announced that a first multiple sclerosis (MS) patient has enrolled in its Phase 2 trial assessing the safety and effectiveness of temelimab in people whose disease is progressing in the absence of relapses. This trial, taking place at the Karolinska Institutet’s Academic Specialist Center (ASC), in Stockholm, had been postponed to reduce…

Loss of myelin in nerve cell fibers — the hallmark of multiple sclerosis (MS) — leads to a shortage of mitochondria, a cell’s powerhouse, denying these damaged fibers the energy they need to work as intended, a new study shows. Boosting the migration of mitochondria to affected nerve…

Tecfidera (dimethyl fumarate) is safe and effective as a long-term treatment for relapsing-remitting multiple sclerosis (RRMS), a study of clinical trial data covering up to 11 years of treatment suggests. The study, “Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis:…

Novartis has awarded a total of $300,000 to two tech companies, honoring each for work done to improve the mobility and independence of people living with multiple sclerosis (MS). The top winner of the Novartis Innovation Prize: Assistive Tech for…

MyHealthTeams and EMD Serono have teamed up to launch the Treatment and Adherence Resource Center, a new informational tool within the MyMSTeam social network for people living with multiple sclerosis (MS). The new resource center is geared toward educating MS patients about the importance of starting…

The National Institute for Health and Care Excellence (NICE) is recommending against Mayzent (siponimod) as a treatment for active secondary progressive multiple sclerosis (SPMS) in the U.K., because its cost-effectiveness relative to an existing treatment for these patients is not known. NICE’s draft guidance for Mayzent is open…

People with multiple sclerosis (MS) exert increased caution with their walking pattern and take smaller steps overall, a study shows. These findings could contribute to the development of better walking rehabilitation programs and decrease the risk of falls. The study, “Influence of Multiple Sclerosis on Dynamic…

A first person has enrolled in Sanofi’s Phase 3 trial evaluating SAR442168, an oral BTK inhibitor intended to treat relapsing forms of multiple sclerosis (MS), Sanofi’s partner, Principia Biopharma, announced. “We are delighted that Sanofi has initiated … [this] trial in patients with relapsing MS,” Roy Hardiman, chief…

Psychosis and cognitive difficulties may be initial symptoms of relapsing‐remitting multiple sclerosis (RRMS), a case report says. “A case report revealing acute onset psychosis and cognitive impairment as primary manifestation in relapsing‐remitting multiple sclerosis” was published in the journal…

A study aiming to better understand falls and fall-related injuries in people with multiple sclerosis (MS) and other neurological disorders while self-isolating during the COVID-19 pandemic is recruiting participants. The online study, largely in the form of a questionnaire, is being carried out by the Motor Control Research…

Generic formulations of dimethyl fumarate — currently sold as Tecfidera by Biogen — were given a green light to enter the U.S. market, after a federal court invalidated a patent protecting Tecfidera from generic competition as a multiple sclerosis (MS) treatment.  The ruling by the District Court for the…